TG Therapeutics, Inc. announced the completion of the rolling submission of a New Drug Application (NDA) to the FDA requesting accelerated approval of umbralisib, the company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with previously treated marginal zone lymphoma and follicular lymphoma.
[TG Therapeutics]
0